Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer

Click here to sign up to receive our monthly PubMed review in your inbox!

Literature Review, April 2018

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Circulating tumor DNA measurement provides reliable mutation detection in mice with human lung cancer xenografts. Wei L1, Xie L1,2, Wang X1, Ma H2, Lv L1, Liu L2, Song X3,4. Lab Invest. 2018 Mar 1. doi: 10.1038/s41374-018-0041-8. [Epub ahead of print]

 

Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. Eaton KD1, Romine PE2, Goodman GE3, Thornquist MD4, Barnett MJ3, Petersdorf EW5. J Thorac Oncol. 2018 Mar 23. pii: S1556-0864(18)30090-X. doi: 10.1016/j.jtho.2018.01.022. [Epub ahead of print]

 

Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer. Shibahara D1, Tanaka K2, Iwama E2, Kubo N2, Ota K2, Azuma K3, Harada T4, Fujita J5, Nakanishi Y2, Okamoto I6. J Thorac Oncol. 2018 Mar 26. pii: S1556-0864(18)30215-6. doi: 10.1016/j.jtho.2018.03.012. [Epub ahead of print]

 

Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer. Xie Y1, Zhang Y2, Du L1, et al. Mol Oncol. 2018 Mar 5. doi: 10.1002/1878-0261.12188. [Epub ahead of print]

 

Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer. Kanaoka R, Iinuma H, Dejima H, Sakai T, Uehara H, Matsutani N, Kawamura M. Oncology. 2018 Mar 13. doi: 10.1159/000487006. [Epub ahead of print]

 

CXCL14 and NOS1 expression in specimens from patients with stage I-IIIA nonsmall cell lung cancer after curative resection. Ji X1, Shen Z, Zhao B, Yuan X, Zhu X. Medicine (Baltimore). 2018 Mar;97(10):e0101. doi: 10.1097/MD.0000000000010101.

SCREENING, DIAGNOISIS AND STAGING

Rapid on-site evaluation using telecytology: A major cancer center experience. Lin O1, Rudomina D1, Feratovic R1, Sirintrapun SJ1. Diagn Cytopathol. 2018 Mar 25. doi: 10.1002/dc.23925. [Epub ahead of print]

 

Benefits and Challenges of Lung Cancer Screening in Older Adults. Fabrikant MS1, Wisnivesky JP2, Marron T3, Taioli E4, Veluswamy RR5. Clin Ther. 2018 Mar 21. pii: S0149-2918(18)30095-X. doi: 10.1016/j.clinthera.2018.03.003. [Epub ahead of print]

 

The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. Fidler MJ1, Fhied CL2, Roder J3, Basu S4, Sayidine S2, Fughhi I1, Pool M2, Batus M1, Bonomi P1, Borgia JA5,6,7. BMC Cancer. 2018 Mar 20;18(1):310. doi: 10.1186/s12885-018-4193-0.

 

Revisions to the TNM Staging of Lung Cancer: Rationale, Significance, and Clinical Application.

Carter BW1, Lichtenberger JP 3rd1, Benveniste MK1, de Groot PM1, Wu CC1, Erasmus JJ1, Truong MT1. Radiographics. 2018 Mar-Apr;38(2):374-391. doi: 10.1148/rg.2018170081.

 

Liquid Biopsy in Tumor Genetic Diagnosis. Jung A1, Kirchner T. Dtsch Arztebl Int. 2018 Mar 9;115(10):169-174. doi: 10.3238/arztebl.2018.0169.

 

Detection of Subsolid Nodules in Lung Cancer Screening: Complementary Sensitivity of Visual Reading and Computer-Aided Diagnosis. Silva M, Schaefer-Prokop CM, Jacobs C, Capretti G, Ciompi F, van Ginneken B, Pastorino U, Sverzellati N. Invest Radiol. 2018 Mar 14. doi: 10.1097/RLI.0000000000000464. [Epub ahead of print]

 

Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review. Jain D, Roy-Chowdhuri S1. Arch Pathol Lab Med. 2018 Mar 16. doi: 10.5858/arpa.2017-0444-RA. [Epub ahead of print]

 

Translation of knowledge to practice – Improving awareness in NSCLC molecular testing.

Zer A1, Cutz JC2, Sekhon H3, et al. J Thorac Oncol. 2018 Mar 10. pii: S1556-0864(18)30187-4. doi: 10.1016/j.jtho.2018.03.005. [Epub ahead of print]

 

Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer. Ray MA1, Faris NR2, Smeltzer MP1, et al. Ann Thorac Surg. 2018 Mar 10. pii: S0003-4975(18)30333-3. doi: 10.1016/j.athoracsur.2018.02.021. [Epub ahead of print]

BACKGROUND: Accurate pathologic nodal staging improves early-stage non-small-cell lung cancer

 

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. Suh JH1, Schrock AB2, Johnson A2, et al. Oncologist. 2018 Mar 14. pii: theoncologist.2017-0493. doi: 10.1634/theoncologist.2017-0493. [Epub ahead of print]

 

Clinical Significance of Molecular Micrometastasis in the Sentinel Lymph Node of Early-stage Non-Small Cell Lung Cancer Patients. Lafuente-Sanchis A1, Estors-Guerrero M2, Zúñiga Á1, et al. Am J Clin Oncol. 2018 Mar 5. doi: 10.1097/COC.0000000000000432. [Epub ahead of print]

 

Genomic Testing in Lung Cancer: Past, Present, and Future. Mascaux C1,1, Tsao MS1, Hirsch FR1. J Natl Compr Canc Netw. 2018 Mar;16(3):323-334. doi: 10.6004/jnccn.2017.7019.

.

 

Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. Noll B1, Wang WL1, Gong Y1, Zhao J1, Kalhor N1, Prieto V1, Staerkel G1, Roy-Chowdhuri S1. Cancer Cytopathol. 2018 Mar 2. doi: 10.1002/cncy.21987. [Epub ahead of print]

 

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Krug AK1, Enderle D1, Karlovich C2, et al. Ann Oncol. 2018 Mar 1;29(3):700-706. doi: 10.1093/annonc/mdx765.

 

Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. Goag EK1, Lee JM1, Chung KS1, et al. J Cancer. 2018 Mar 2;9(6):1113-1120. doi: 10.7150/jca.21650. eCollection 2018.

 

Lung Cancer Screening in the Community Setting. Cattaneo SM 2nd1, Meisenberg BR2, Geronimo MCM3, Bhandari B3, Maxted JW3, Brady-Copertino CJ2. Ann Thorac Surg. 2018 Mar 1. pii: S0003-4975(18)30262-5. doi: 10.1016/j.athoracsur.2018.01.075. [Epub ahead of print]

 

Early Results From the Implementation of a Lung Cancer Screening Program: The Beaumont Health System Experience. Lanni TB Jr1, Stevens C2, Farah M3, Boyer A3, Davis J3, Welsh R4, Keena D5, Akhtar A6, Mezwa D3. Am J Clin Oncol. 2018 Mar;41(3):218-222. doi: 10.1097/COC.0000000000000254.

 

Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling. Plagnol V1, Woodhouse S1, Howarth K1, et al. PLoS One. 2018 Mar 15;13(3):e0193802. doi: 10.1371/journal.pone.0193802. eCollection 2018.

 

Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC Patients. Feng WN1, Gu WQ2, Zhao N2, Pan YM3, Luo W3, Zhang H1, Liang JM1, Yang J2, Deng YM4. Transl Oncol. 2018 Apr;11(2):542-545. doi: 10.1016/j.tranon.2018.02.007. Epub 2018 Mar 8.

NSCLC SURGERY

Differences in postoperative changes in pulmonary functions following segmentectomy compared with lobectomy. Nomori H1, Shiraishi A2, Cong Y1, Sugimura H1, Mishima S1. Eur J Cardiothorac Surg. 2018 Mar 1;53(3):640-647. doi: 10.1093/ejcts/ezx357.

postoperative increase in regional functions could be the result of compensatory lung growth.

 

Long-Term Results for Clinical Stage IA Lung Cancer- Comparing Lobectomy and Sublobar Resection. Subramanian M1, McMurry T2, Meyers BF1, Puri V1, Kozower BD3. Ann Thorac Surg. 2018 Mar 23. pii: S0003-4975(18)30387-4. doi: 10.1016/j.athoracsur.2018.02.049. [Epub ahead of print]

trial results comparing these treatments are extrapolated for clinical use.

 

Should surgery be part of the multimodality treatment for stage IIIB non-small cell lung cancer?

Collaud S1, Provost B1, Besse B2, Fabre D1, Le Chevalier T1,2, Mercier O1, Mussot S1, Fadel E1. J Surg Oncol. 2018 Mar 24. doi: 10.1002/jso.25042. [Epub ahead of print]

encouraging 5-year survival of 39%.

 

Favourable outcomes in patients with early-stage non-small-cell lung cancer operated on by video-assisted thoracoscopic surgery: a propensity score-matched analysis. Dziedzic R1, Marjanski T1, Binczyk F2, Polanska J2, Sawicka W3, Rzyman W1. Eur J Cardiothorac Surg. 2018 Mar 14. doi: 10.1093/ejcts/ezy101. [Epub ahead of print]

 

Robotic Versus Video-Assisted Thoracoscopic Lung Resection During Early Program Development. Kaur MN1, Xie F2, Shiwcharan A3, Patterson L4, Shargall Y5, Finley C5, Schieman C6, Dalimonte T7, Fahim C8, Hanna WC9. Ann Thorac Surg. 2018 Apr;105(4):1050-1057. doi: 10.1016/j.athoracsur.2017.11.013. Epub 2018 Mar 2.

NSCLC – SYSTEMIC THERAPIES (CHEMOTHERAPY, TARGETED THERAPY, AND IMMUNOTHERAPY)

Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.

Frankel D1, Nanni-Metellus I2, Robaglia-Schlupp A1, et al. Clin Chem Lab Med. 2018 Jan 8. pii: /j/cclm.ahead-of-print/cclm-2017-0527/cclm-2017-0527.xml. doi: 10.1515/cclm-2017-0527. [Epub ahead of print]

 

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Garassino MC1, Cho BC2, Kim JH3, et al. Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

durvalumab in patients with EGFR+/ALK+ NSCLC is warranted. FUNDING: AstraZeneca.

 

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. Gettinger S1, Horn L1, Jackman D1, et al. J Clin Oncol. 2018 Mar 23:JCO2017770412. doi: 10.1200/JCO.2017.77.0412. [Epub ahead of print]

 

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).

Hirsch FR1, Sequist LV2, Gore I3, et al. Cancer. 2018 Mar 26. doi: 10.1002/cncr.31313. [Epub ahead of print]

Society.

 

The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer. Gadgeel SM1. Future Oncol. 2018 Mar 14. doi: 10.2217/fon-2018-0027. [Epub ahead of print]

 

Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. Sabatier R1, Nicolas E2, Paciencia M3, et al. J Geriatr Oncol. 2018 Mar 9. pii: S1879-4068(18)30090-0. doi: 10.1016/j.jgo.2018.02.011. [Epub ahead of print]

 

A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer. Park CK1, Oh IJ1, Choi YD2, Jang TW3, Lee JE4, Ryu JS5, Lee SY6, Kim YC1. Oncology. 2018 Mar 2. doi: 10.1159/000486896. [Epub ahead of print]

 

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Goss G1, Tsai CM2, Shepherd FA3, et al. Ann Oncol. 2018 Mar 1;29(3):687-693. doi: 10.1093/annonc/mdx820.

 

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016. Ikeda S1, Kato T2,3, et al. BMC Cancer. 2018 Mar 2;18(1):241. doi: 10.1186/s12885-018-4150-y.

 

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. Haratani K1, Hayashi H1, Chiba Y2, et al. JAMA Oncol. 2018 Mar 1;4(3):374-378. doi: 10.1001/jamaoncol.2017.2925.

advanced or recurrent NSCLC. Further studies are needed to confirm our findings.

 

Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809.  Niho S1, Ikeda N2, Michimae H3, et al. Am J Clin Oncol. 2018 Mar 7. doi: 10.1097/COC.0000000000000438. [Epub ahead of print]

 

Stromal PDGFR-β Expression is Associated with Postoperative Survival of Non-Small Cell Lung Cancer Patients Receiving Preoperative Chemo- or Chemoradiotherapy Followed by Surgery.

Kanzaki R1, Ose N2, Kawamura T2, Funaki S2, Shintani Y2, Minami M2, Takakura N3, Okumura M2. World J Surg. 2018 Mar 6. doi: 10.1007/s00268-018-4560-7. [Epub ahead of print]

 

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-line Treatment of ALK Translocation-Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). Spigel DR1, Reynolds C2, Waterhouse D3, et al. J Thorac Oncol. 2018 Mar 5. pii: S1556-0864(18)30176-X. doi: 10.1016/j.jtho.2018.02.022. [Epub ahead of print]

 

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-line Treatment of ALK Translocation-Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). Spigel DR1, Reynolds C2, Waterhouse D3, et al. J Thorac Oncol. 2018 Mar 5. pii: S1556-0864(18)30176-X. doi: 10.1016/j.jtho.2018.02.022. [Epub ahead of print]

NSCLC - RADIOTHERAPY

Volumetric modulated arc therapy treatment planning of thoracic vertebral metastases using stereotactic body radiotherapy. Mallory M1, Pokhrel D2, Badkul R1, Jiang H1, Lominska C1, Wang F1. J Appl Clin Med Phys. 2018 Jan 19. doi: 10.1002/acm2.12252. [Epub ahead of print]

 

Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives. Donovan EK1,2, Swaminath A1,2. Lung Cancer (Auckl). 2018 Mar 16;9:13-23. doi: 10.2147/LCTT.S129833. eCollection 2018.

Changes in Treatment Patterns and Overall Survival in Patients With Early-Stage Non-Small Cell Lung Cancer in the United States After the Incorporation of Stereotactic Ablative Radiation Therapy: A Population-based Analysis. Haque W1, Szeja S2, Tann A2, Kalra S3, Teh BS4.

Am J Clin Oncol. 2018 Mar;41(3):259-266. doi: 10.1097/COC.0000000000000265.

 

A model combining age, equivalent uniform dose and IL-8 may predict radiation esophagitis in patients with non-small cell lung cancer.

Wang S1, Campbell J2, Stenmark MH3, Stanton P2, Zhao J2, Matuszak MM3, Ten Haken RK3, Kong FM4. Radiother Oncol. 2018 Mar;126(3):506-510. doi: 10.1016/j.radonc.2017.12.026.

 

Radiomics analysis at PET/CT contributes to prognosis of recurrence and survival in lung cancer treated with stereotactic body radiotherapy. Oikonomou A1, Khalvati F2, Tyrrell PN3, et al. Sci Rep. 2018 Mar 5;8(1):4003. doi: 10.1038/s41598-018-22357-y.

 

A Methodology to Investigate the Impact of Image Distortions on the Radiation Dose When Using Magnetic Resonance Images for Planning. Yan Y1, Yang J2, Beddar S3, et al. Phys Med Biol. 2018 Mar 12. doi: 10.1088/1361-6560/aab5c3. [Epub ahead of print]

 

Stereotactic ablative radiation therapy in lung cancer: an emerging standard. Mutsaers A1, Chen H, Louie AV. Curr Opin Pulm Med. 2018 Mar 7. doi: 10.1097/MCP.0000000000000482. [Epub ahead of print]

SMALL CELL LUNG CANCER - SCLC

Randomized Phase III Trial of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer. Kim DW1, Kim HG2, Kim JH3, et al. Cancer Res Treat. 2018 Mar 12. doi: 10.4143/crt.2018.019. [Epub ahead of print]

 

The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer. Miura Y1,2, Imai H3, Sakurai R2,4, Kaira K5, Sunaga N2, Minato K1, Saito R4, Hisada T2. Med Oncol. 2018 Mar 5;35(4):45. doi: 10.1007/s12032-018-1107-6.

 

Targeting CREB pathway suppresses Small Cell lung Cancer. Xia Y1, Zhan C2, Feng M2, Leblanc M3, Ke E4, Yeddula N5, Verma IM6. Mol Cancer Res. 2018 Mar 9. pii: molcanres.0576.2017. doi: 10.1158/1541-7786.MCR-17-0576. [Epub ahead of print]

 

Adjuvant chemotherapy following surgical resection improves survival in patients with early-stage small cell lung cancer. Yao Y1, Zhou Y1, Yang Z1, Huang H1, Shen H1. Oncol Res. 2018 Mar 9. doi: 10.3727/096504018X15202953107093. [Epub ahead of print]

 

A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer. Subramaniam DS1, Liu SV1, Crawford J2, Kramer J1, Thompson J1, Wang H2, Giaccone G2. Front Oncol. 2018 Mar 12;8:64. doi: 10.3389/fonc.2018.00064. eCollection 2018.

PALLIATIVE AND SUPPORTIVE CARE

Patients with advanced cancer and depression report a significantly higher symptom burden than non-depressed patients.

Grotmol KS1, Lie HC2, Loge JH1, Aass N3, Haugen DF4, Stone PC5, Kaasa S6, Hjermstad MJ1. Palliat Support Care. 2018 Jan 10:1-7. doi: 10.1017/S1478951517001183. [Epub ahead of print]

 

Does depression treatment improve the survival of depressed patients with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials. Mulick A1, Walker J2, Puntis S2, Burke K2, Symeonides S3, Gourley C3, Wanat M2, Frost C1, Sharpe M4. Lancet Psychiatry. 2018 Apr;5(4):321-326. doi: 10.1016/S2215-0366(18)30061-0. Epub 2018 Mar 12.

BACKGROUND: Comorbid major depression has been associated with worse survival in patients with

 

18F-FDG PET/CT Can Predict Development of Thyroiditis due to Immunotherapy for Lung Cancer. Eshghi N1, Garland L1, Nia ES2, Betancourt R1, Krupinski E3, Kuo PH1. J Nucl Med Technol. 2018 Mar 29. pii: jnmt.117.204933. doi: 10.2967/jnmt.117.204933. [Epub ahead of print]

 

Cancer Pain Management Education Rectifies Patients’ Misconceptions of Cancer Pain, Reduces Pain, and Improves Quality of Life. Koh SJ1, Keam B2, Hyun MK3, Ju Seo J4, Uk Park K5, Oh SY6, Ahn J4, Lee JY7, Kim J8. Pain Med. 2018 Mar 26. doi: 10.1093/pm/pny039. [Epub ahead of print]

 

Sleepless from the Get Go: Sleep Problems Prior to Initiating Cancer Treatment. Zhou ES1,2, Clark K3, Recklitis CJ4,5, Obenchain R3, Loscalzo M3. Int J Behav Med. 2018 Mar 15. doi: 10.1007/s12529-018-9715-2. [Epub ahead of print]

 

Efficacy of a Propolis-Based Syrup (FARINGEL) in Preventing Radiation-Induced Esophagitis in Locally Advanced Lung Cancer. Ippolito E, Floreno B, Rinaldi CG, Trodella L, Meroni FL, Iurato A, D’Angelillo RM, Ramella S, Fiore M. Chemotherapy. 2018 Mar 19;63(2):76-82. doi: 10.1159/000487897. [Epub ahead of print]

 

Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non-Small-Cell Lung Cancer. Lau SKM1, Gannavarapu BS1, Carter K1, Gao A1, Ahn C1, Meyer JJ1, Sher DJ1, Jatoi A1, Infante R1, Iyengar P1. J Oncol Pract. 2018 Mar 20:JOP2017025239. doi: 10.1200/JOP.2017.025239. [Epub ahead of print]

 

Changes in exercise tolerance and quality of life are unrelated in lung cancer survivors who undergo video-assisted thoracic surgery. Anami K1,2, Horie J3, Hirayama Y4, Yamashita N5, Ito K6. J Phys Ther Sci. 2018 Mar;30(3):467-473. doi: 10.1589/jpts.30.467. Epub 2018 Mar 2.

 

Relationships Between Smoking Status and Psychological Distress, Optimism, and Health Environment Perceptions at Time of Diagnosis of Actual or Suspected Lung Cancer.

Choi SH1, Chan RR, Lehto RH. Cancer Nurs. 2018 Mar 13. doi: 10.1097/NCC.0000000000000579. [Epub ahead of print]

 

Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Bar-Lev Schleider L1, Mechoulam R2, Lederman V3, Hilou M3, Lencovsky O4, Betzalel O3, Shbiro L4, Novack V5. Eur J Intern Med. 2018 Mar;49:37-43. doi: 10.1016/j.ejim.2018.01.023.

 

The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Turcott JG1, Del Rocío Guillen Núñez M2, Flores-Estrada D1, Oñate-Ocaña LF3, Zatarain-Barrón ZL1, Barrón F1, Arrieta O4. Support Care Cancer. 2018 Mar 17. doi: 10.1007/s00520-018-4154-9. [Epub ahead of print]

 

Lung cancer and family-centered patient concerns. Feliciano J1, Becker B2, Shukla M2, Bodurtha J3. Support Care Cancer. 2018 Mar 21. doi: 10.1007/s00520-018-4159-4. [Epub ahead of print]

COMPLEMENTARY & ALTERNATIVE THERAPY

Lemongrass essential oil and citral inhibit Src/Stat3 activity and suppress the proliferation/survival of small-cell lung cancer cells, alone or in combination with chemotherapeutic agents.

Maruoka T1, Kitanaka A2, Kubota Y3, et al. Int J Oncol. 2018 Mar 13. doi: 10.3892/ijo.2018.4314. [Epub ahead of print]

 

Ameliorative effects of Tai Chi on cancer-related fatigue: a meta-analysis of randomized controlled trials. Song S1, Yu J1, Ruan Y2, Liu X1, Xiu L1, Yue X3. Support Care Cancer. 2018 Mar 21. doi: 10.1007/s00520-018-4136-y. [Epub ahead of print]

 

Structural characterization of a polysaccharide from the flower buds of Tussilago farfara, and its effect on proliferation and apoptosis of A549 human non-small lung cancer cell line. Qu H1, Yang W2, Li J3. Int J Biol Macromol. 2018 Mar 2;113:849-858. doi: 10.1016/j.ijbiomac.2018.03.005. [Epub ahead of print]

 

Regulatory roles of OASL in lung cancer cell sensitivity to Actinidia chinensis Planch root extract (acRoots). Lv J1, Wang L2, Shen H3, Wang X4,5. Cell Biol Toxicol. 2018 Mar 5. doi: 10.1007/s10565-018-9422-4. [Epub ahead of print]

 

Naturopathic Oncology Care for Thoracic Cancers: A Practice Survey. Seely D1,2, Ennis JK1,2, McDonell E1,2, Zhao L1,2. Integr Cancer Ther. 2018 Mar 1:1534735418759420. doi: 10.1177/1534735418759420. [Epub ahead of print]

MISCELLANEOUS WORKS

Survival among Lung Cancer Patients in the U.S. Military Health System: A Comparison with the SEER population. Lin J1, Kamamia C2, Brown D3, Shao S2, McGlynn KA4, Nations JA2, Carter CA2, Shriver CD2, Zhu K2. Cancer Epidemiol Biomarkers Prev. 2018 Mar 12. pii: cebp.0822.2017. doi: 10.1158/1055-9965.EPI-17-0822. [Epub ahead of print]

 

Project Transform: engaging patient advocates to share their perspectives on improving research, treatment and policy. Bridges JFP1,2, Janssen EM1, Ferris A3, Dy SM1,4. Curr Med Res Opin. 2018 Mar 9:1-8. doi: 10.1080/03007995.2018.1440199. [Epub ahead of print]

 

Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer. Shin JY1, Yoon JK2, Marwaha G2. Lung. 2018 Mar 17. doi: 10.1007/s00408-018-0110-1. [Epub ahead of print]

 

Smoking-related health beliefs and smoking behavior in the National Lung Screening Trial.

Kaufman AR1, Dwyer LA2, Land SR3, Klein WMP4, Park ER5. Addict Behav. 2018 Mar 14;84:27-32. doi: 10.1016/j.addbeh.2018.03.015. [Epub ahead of print]

 

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in Twenty-Six Patients with Advanced Non-Small Cell Lung Cancer. Gettinger SN1, Wurtz A2, Goldberg SB2, et al. J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30210-7. doi: 10.1016/j.jtho.2018.03.008. [Epub ahead of print]

 

Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 – 2013. Lynch JA1,2, Berse B3,4, Rabb M5, Mosquin P5, Chew R5, West SL5, Coomer N5, Becker D6,7, Kautter J3. BMC Cancer. 2018 Mar 20;18(1):306. doi: 10.1186/s12885-018-4190-3.

 

Time-to-Treatment-Failure and Related Outcomes among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients. Gajra A1, Zemla TJ2, Jatoi A2, et al. J Thorac Oncol. 2018 Mar 30. pii: S1556-0864(18)30254-5. doi: 10.1016/j.jtho.2018.03.020. [Epub ahead of print]

 

Cancer survival among Alaska Native people. Nash SH1, Meisner ALW2, Zimpelman GL1, Barry M2,3, Wiggins CL2,4. Cancer. 2018 Mar 26. doi: 10.1002/cncr.31350. [Epub ahead of print]

Archives